Compare Pfizer Inc (PFE) vs Nuscale Power Corporation (SMR) Price & Performance

Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.

PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.

SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company shows severe fundamental challenges with negative net income margins exceeding -2,000% and consecutive earnings misses. Despite these losses, analyst consensus remains optimistic with a $12.25 price target representing 54% upside potential, driven by nuclear energy's long-term prospects and the company's first-mover advantage in small modular reactors.

The stock presents a high-risk, high-reward opportunity. While current financials are deeply concerning with massive losses and negative cash flow, the potential nuclear energy renaissance and SMR's regulatory approvals offer substantial upside if commercialization succeeds. Investors face significant execution risk as the company burns cash while attempting to secure its first commercial reactor sale.